Cannabis Tolerance Claims: Questions to Ask Before Relying on Expert Testimony
A history of frequent marijuana use does not, by itself, establish that a person was unaffected by THC. A claim of tolerance needs to identify the function at issue, the comparison being made, and the evidence supporting that comparison. The same care applies to the opposite claim: population research does not determine an individual’s condition during an unobserved incident.
Start by defining the claimed tolerance
“Tolerance” can refer to feeling less intoxicated, showing a smaller physiological response, or experiencing less disruption on a particular performance task. Those propositions require different evidence. In reviewing testimony, first ask what the witness means by the term. An opinion about subjective familiarity should not silently become an opinion about divided attention or emergency decision-making.
The supplied research: a 122-person crossover experiment
Ramaekers and colleagues compared acute cannabis, placebo, and an active cocaine control in separate experimental sessions. The 122 completers had histories of both cannabis and cocaine use. Their cannabis-use frequencies ranged from infrequent to daily. The design allowed researchers to compare each participant’s performance across treatment conditions.
The cannabis challenge supplied 300 micrograms of THC per kilogram by vaporization. The study evaluated planning, response inhibition, divided attention, tracking, and reported intoxication. It therefore tested several functions rather than treating impairment as one interchangeable endpoint.
Why the comparator matters
The supplied study record describes worse performance after THC on several tasks, with most cannabis effects not significantly modified by prior-use frequency. Critical tracking presented a more complicated picture: its interaction with use history required attention to differences in placebo-session performance.
That qualification matters when reviewing a tolerance opinion. A smaller change between active treatment and placebo does not necessarily mean that the active-treatment performance was normal. The starting point can affect the size of the calculated change. Ask to see both conditions, the relevant endpoint, and the variability rather than accepting a single description of “less impairment.”
| Proposed inference | Question to resolve |
|---|---|
| Frequent use proves tolerance | Tolerance to which measured effect, and established by what evidence? |
| A smaller treatment difference proves normal functioning | How did the comparison group or placebo baseline perform? |
| One unaffected task proves general safety | Were the other relevant functions tested, and what were their results? |
| A laboratory finding decides an individual case | How do the population, dose, route, timing, and task relate to the actual event? |
Use history is context, not a complete reconstruction
A useful records review documents the reported frequency of use, product, route, timing, and available observations. It also separates those historical facts from the specimen result. This experiment measured cannabinoids in serum; a serum concentration should not be relabeled as whole blood or treated as an individual driving-performance measurement.
The participants’ drug histories and the controlled laboratory setting also limit generalization. The experiment did not recreate a particular collision, workplace incident, or roadside examination. Its relevance is to the scientific foundation of a proposed generalization about tolerance.
Questions to ask before relying on the opinion
- Is the witness discussing subjective intoxication or an objectively measured function?
- Does the cited research actually compare frequent and infrequent users?
- Are the conclusion and the measured endpoint the same?
- Were baseline differences and nonsignificant results addressed?
- What additional evidence connects the research to this person and this event?
For the broader distinction between exposure and case-specific conclusions, see Cannabis DUI Evidence: Four Questions That Must Remain Separate and THC Blood Levels and Impairment Evidence.
Primary research
Ramaekers JG, van Wel JH, Spronk DB, et al. Cannabis and tolerance: acute drug impairment as a function of cannabis use history. Scientific Reports. 2016;6:26843. doi:10.1038/srep26843. The journal also published an author-contributions erratum.
